Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	132.19	132.19	151.02	149.16	152.11	29.25
Cash & Short-Term Investments	132.19	132.19	151.02	149.16	152.11	29.25
Cash Growth	-12.47%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Other Receivables	2.45	2.45	2.71	3.19	9.14	4.85
Receivables	2.45	2.45	2.71	3.19	9.14	4.85
Prepaid Expenses	0.93	0.93	0.65	0.35	0.37	0.44
Total Current Assets	135.57	135.57	154.39	152.71	161.62	34.54
Total Assets	135.57	135.57	154.39	152.71	161.62	34.54
Accounts Payable	9.63	9.63	4.32	3.83	4.74	3.99
Accrued Expenses	4.84	4.84	7.3	5.95	5.61	3.32
Current Unearned Revenue	0.84	0.84	0.92	0.44	0.44	-
Total Current Liabilities	15.3	15.3	12.53	10.21	10.8	7.31
Total Liabilities	15.3	15.3	12.53	10.21	10.8	7.31
Common Stock	0.09	0.09	0.08	0.08	0.08	0.06
Additional Paid-In Capital	456.25	456.25	434.84	387.98	348.33	186.85
Retained Earnings	-336.07	-336.07	-293.07	-245.56	-197.59	-159.68
Shareholders' Equity	120.26	120.26	141.85	142.49	150.82	27.24
Total Liabilities & Equity	135.57	135.57	154.39	152.71	161.62	34.54
Net Cash (Debt)	132.19	132.19	151.02	149.16	152.11	29.25
Net Cash Growth	-12.47%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Net Cash Per Share	1.58	1.58	1.89	1.94	2.18	0.50
Filing Date Shares Outstanding	84.82	84.82	82.09	77.96	76.02	66.96
Total Common Shares Outstanding	84.8	84.8	82.07	77.94	75.92	62.05
Working Capital	120.26	120.26	141.85	142.49	150.82	27.24
Book Value Per Share	1.42	1.42	1.73	1.83	1.99	0.44
Tangible Book Value	120.26	120.26	141.85	142.49	150.82	27.24
Tangible Book Value Per Share	1.42	1.42	1.73	1.83	1.99	0.44

Source: S&P Capital IQ. Standard template. Financial Sources.